[go: up one dir, main page]

WO1996029045A1 - Compostions antipelliculaires - Google Patents

Compostions antipelliculaires Download PDF

Info

Publication number
WO1996029045A1
WO1996029045A1 PCT/US1996/003988 US9603988W WO9629045A1 WO 1996029045 A1 WO1996029045 A1 WO 1996029045A1 US 9603988 W US9603988 W US 9603988W WO 9629045 A1 WO9629045 A1 WO 9629045A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
treatment
dandruff
composition
antifungal agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/003988
Other languages
English (en)
Inventor
Avi Dascalu
Yoram Oron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Priority to AU55261/96A priority Critical patent/AU5526196A/en
Priority to US08/913,650 priority patent/US6075017A/en
Publication of WO1996029045A1 publication Critical patent/WO1996029045A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • the invention relates to pharmaceutical compositions for use in the treatment of seborrheic dermatitis of the scalp.
  • Dandruff seborrheic dermatitis of the scalp, is a common disease involving 3-5% of the population. Dandruff is, in many cases, the precursor of alopecia (baldness) and constitutes a chronic and almost intractable cosmetical and social inconvenience. The pathophysiology of the disease remains unknown, although it is known to involve a hyperproliferat ⁇ ive state of the skin, a limited inflammatory process, and a secondary microbial colonization by the lipophilic yeast Pityrosporum, which is abundant and significantly ovcrpopulated on the scalp of seborrheic patients. Dandruff is a chronic and almost incurable disease. Available treatments result only in short term effects with an eventual recurrence of the disease.
  • a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
  • a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
  • the present invention provides by a first of its aspects a composition, e g in the form of a hair shampoo, for the treatment of dandruff or of symptoms associated therewith, comprising in combination an effective amount of at least one cytotoxic agent and an effective amount of at least one antifungal agent, together with a carrier, a diluent or an excipient
  • effective amount means to denote an amount of an agent effective in achieving a therapeutic result in the treatment of dandruff, such as alleviation of itching, a decrease in the amount of scales, a reduction in the rate of hair loss, a reduction in scalp redness, etc.
  • cytotoxic agent as used herein means to denote an agent which inhibits proliferation of keratinocytes skin cells.
  • antifungal agent will be used to denote an agent which is specifically active in inhibiting growth of fungus and the fungus' ability to colonize the skin, which includes, inter alia, agents which are destructive to fungi, or active in suppressing growth of fungus or affect their ability to reproduce
  • cytotoxic agent refers to agents which arc known in the art primarily by having cytotoxic activity
  • antifungal agent refers to agents which are known in the art primarily by their antifungal activity
  • cytotoxic agents useful in accordance with the invention are coal tars, selenium sulfide, zinc pyrithione or the like.
  • the preferred cytoxic agent is coal tar, typically included in the composition in concentration of 1-5%.
  • antifungal agents useful in accordance with the invention include imidazoles, ciclopiroxolamines and metronidazolcs.
  • the imidazoles which arc preferred in accordance with the invention, include ketoconozole, bifonazole, itraconazolc, cconazole, clotrimazole, miconazole, oxiconazole, isoconazolc and the like. From the imidazoles, ketoconozole is particularly preferred.
  • the antifungal agent is included in the composition in a concentration of 0.5-5%
  • the present invention further provides the use of said cytotoxic agent in combination with said antifungal agent for the preparation of a composition, e.g. a medical hair shampoo, for the treatment of dandruff.
  • a composition e.g. a medical hair shampoo
  • a further aspect of the invention is concerned with the treatment of individuals suffering from dandruff by combined application to the scalp of such individuals of said cytotoxic agent and of said antifungal agent.
  • the individuals may be treated by the use of a single composition, e.g. in the form of a hair shampoo, comprising both agents.
  • the individuals may be treated by a combination of two different compositions, one comprising said cytotoxic agent and the other said antifungal agent. The above described combination may be applied 3-4 times during the first week from the start of the treatment, and 1-2 times a week, thereafter.
  • the present invention also pertains to a package comprising at least two compositions, one comprising said antifungal agent and the other said cytotoxic agent, optionally with instructions for use in said method.
  • Example 1 A group of six patients (ages 17-38) with a severe case of dandruff were on a regular bi-weekly anti seborrheic treatment prior to the onset of the experiment. During the experiment they were treated with a combination of the following two compositions: a. a composition comprising 1.8% coal tar. b. a solution comprising 2% kctoconazole.
  • the patients were instructed to apply the two compositions, one after the other, in an amount sufficient to cover the entire scalp.
  • the patients were instructed to apply the compositions on days 1 , 3, 6 and 9.
  • the patients' conditions were examined after 14 or 30 days following the onset of treatment.
  • the patients' conditions were evaluated by the following criteria: (i) scaling - existence of scales on the scalp, typically at the temporal area; (ii) itching - based on the patient's subjective feeling; (iii) severity - overall assessment of the dandruff disease situation, taking into account the skin redness as an indication of inflammatorv conditions. - D -
  • Example 1 A group of three patients who had no record of treatment for dandruff prior to the onset of the experiment, was given the same treatment as in Example 1. The patients' condition was as severe as in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On traite l'eczéma séborrhéique du cuir chevelu au moyen d'une combinaison d'un agent cytotoxique et d'un agent antifongique.
PCT/US1996/003988 1995-03-21 1996-03-20 Compostions antipelliculaires Ceased WO1996029045A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU55261/96A AU5526196A (en) 1995-03-21 1996-03-20 Compositions for the treatment of dandruff
US08/913,650 US6075017A (en) 1995-03-21 1996-03-20 Compositions for the treatment of dandruff

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL113057 1995-03-21
IL11305795A IL113057A (en) 1995-03-21 1995-03-21 Compositions for the treatment of dandruff

Publications (1)

Publication Number Publication Date
WO1996029045A1 true WO1996029045A1 (fr) 1996-09-26

Family

ID=11067236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003988 Ceased WO1996029045A1 (fr) 1995-03-21 1996-03-20 Compostions antipelliculaires

Country Status (3)

Country Link
AU (1) AU5526196A (fr)
IL (1) IL113057A (fr)
WO (1) WO1996029045A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029733A1 (fr) * 1996-02-16 1997-08-21 Janssen Pharmaceutica N.V. Compositions contenant un antifongique et un compose soufre
WO1999030675A1 (fr) * 1997-12-18 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Methodes permettant d'ameliorer l'etat du cheveu et du cuir chevelu
WO2000006144A1 (fr) * 1998-07-27 2000-02-10 Howard Murad Compositions pharmaceutiques et methodes de lutte contre des affections du cuir chevelu
WO2001012140A1 (fr) * 1999-08-13 2001-02-22 Clariant Gmbh Preparations cosmetiques
US6469033B1 (en) 1996-09-27 2002-10-22 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
US6916479B2 (en) 1997-04-14 2005-07-12 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
US7018656B2 (en) 1996-09-27 2006-03-28 Aventis Pharma Deutschland Gmbh Antimycotic gel with high active substance release
RU2311904C1 (ru) * 2006-02-09 2007-12-10 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Способ лечения микроспории кошек
US7981909B2 (en) 1996-09-27 2011-07-19 Medicis Pharmaceutical Corporation Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
US4518789A (en) * 1982-06-30 1985-05-21 Yu Ruey J Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
US4518789A (en) * 1982-06-30 1985-05-21 Yu Ruey J Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029733A1 (fr) * 1996-02-16 1997-08-21 Janssen Pharmaceutica N.V. Compositions contenant un antifongique et un compose soufre
US7018656B2 (en) 1996-09-27 2006-03-28 Aventis Pharma Deutschland Gmbh Antimycotic gel with high active substance release
US6469033B1 (en) 1996-09-27 2002-10-22 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
US7026337B2 (en) 1996-09-27 2006-04-11 Aventis Pharma Deutschland Gmbh Antimycotic gel having high active compound release
US7981909B2 (en) 1996-09-27 2011-07-19 Medicis Pharmaceutical Corporation Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US6916479B2 (en) 1997-04-14 2005-07-12 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
US6099870A (en) * 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
WO1999030675A1 (fr) * 1997-12-18 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Methodes permettant d'ameliorer l'etat du cheveu et du cuir chevelu
WO2000006144A1 (fr) * 1998-07-27 2000-02-10 Howard Murad Compositions pharmaceutiques et methodes de lutte contre des affections du cuir chevelu
WO2001012140A1 (fr) * 1999-08-13 2001-02-22 Clariant Gmbh Preparations cosmetiques
DE19938404A1 (de) * 1999-08-13 2001-02-22 Clariant Gmbh Kosmetische Zubereitungen
US6663875B2 (en) 1999-08-13 2003-12-16 Clariant Gmbh Hair preparation for the treatment of dandruff
RU2311904C1 (ru) * 2006-02-09 2007-12-10 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Способ лечения микроспории кошек

Also Published As

Publication number Publication date
IL113057A0 (en) 1995-06-29
IL113057A (en) 1999-01-26
AU5526196A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
Faergemann Management of seborrheic dermatitis and pityriasis versicolor
EP0961609B1 (fr) Methodes permettant d'ameliorer l'etat du cheveu et du cuir chevelu
EP0500745B1 (fr) Compositions de metaux-peptides et procede cosmetique pour la stimulation de la croissance des cheveux
EP0737471A2 (fr) Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
EP0673643B1 (fr) Composition cosmétique contenant en association une superoxyde dismutase et une porphyrine
WO1996029045A1 (fr) Compostions antipelliculaires
US6673842B2 (en) Method of treating onychomycosis
US6075017A (en) Compositions for the treatment of dandruff
JP5694382B2 (ja) ジベンゾ−ｐ−ジオキシン誘導体を含む脱毛防止および毛髪の生長促進用組成物
US6986896B2 (en) Method of treating fungal conditions of the skin
WO1999044579A2 (fr) Utilisation d'un compose inhibant l'activite d'un canal sodium ou d'un canal calcium dans une composition a usage topique
FR2769838A1 (fr) Utilisation de derives d'azole pour la preparation d'une composition dermatologique ou cosmetologique
Ive An overview of experience with ketoconazole shampoo
US20090197954A1 (en) Linoleic acid preparations for the topical treatment of male and female pattern androgenetic alopecia, age-related alopecia, and keratosis pilaris
Nakagawa et al. Comparative study of FK506 (tacrolimus) ointment vs. alclometasone dipropionate ointment in atopic dermatitis (face and neck lesions)
KR20220071218A (ko) 비듬에 대응하기 위한 시클로피록스올라민 및 피록톤 올라민의 조합물
FR2758263A1 (fr) Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
RU2832017C1 (ru) Комбинация циклопироксоламина и пироктоноламина для борьбы с перхотью
US20250339358A1 (en) Novel use of a blend of sugars comprising psicose, mannose, fructose and glucose
JPH0112725B2 (fr)
McGavack et al. A clinical investigation of beta-morpholino-ethyl benzhydryl ether hydrochloride (linadryl) as an antihistamine agent
Der-Petrossian et al. Halfside comparison study on the efficacy of 8-MOP bath-PUVA versus narrow-band UVB phototherapy in patients with severe atopic dermatitis
KR100454149B1 (ko) 해면추출액을 함유하는 모발화장료 조성물
Metze et al. Hydroxyethylstarch (HES)-associated pruritus as a result of long-term storage in cutaneous nerves
KR20090039458A (ko) 편백 오일를 함유한 비듬균 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08913650

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA